Partially complementary RNA

Partially complementary RNA refers to a functional class of RNA molecules that engage in base-pairing interactions characterized by imperfect sequence matching, such as bulges or mismatches. This phenomenon is central to post-transcriptional gene regulation, most notably in the microRNA (miRNA) pathway, where miRNAs bind to partially complementary sequences in the 3' untranslated regions (UTRs) of target messenger RNAs (mRNAs) to induce translational repression or degradation (NIH; Nature Reviews Drug Discovery). Beyond endogenous regulation, partial complementarity is a key consideration in the development of RNA-based therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as it dictates both the potency of on-target silencing and the risk of off-target effects (MDPI; RSC). Synthetic partially complementary RNAs, such as mismatched double-stranded RNAs like rintatolimod, are also utilized as therapeutic agents to stimulate the innate immune system via receptors like Toll-like receptor 3 (TLR3) (Nature; ResearchGate). Furthermore, long partially complementary RNAs formed from inverted repeats are primary sites for RNA editing enzymes, which can be dysregulated in various malignancies (NIH; TCGA). Dysregulation of these RNA-RNA interactions is implicated in diseases such as cancer, viral infections, and neurodegenerative disorders, making them significant focal points for drug discovery and molecular diagnostics (PLOS Pathogens; Google Scholar).

Other names

Mismatched RNAImperfectly complementary RNAmiRNA-target complexRNA-RNA duplexMismatched double-stranded RNA

Drugs targeting partially complementary RNAs typically act through RNA interference (RNAi), translational inhibition, or mRNA degradation. For example, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) bind to target RNAs to trigger their destruction or block their function, while antagomirs specifically sequester microRNAs to prevent them from binding to their partially complementary targets. Additionally, synthetic mismatched double-stranded RNAs can act as agonists for pattern recognition receptors like TLR3.